How does telotristat ethyl stop carcinoid diarrhea?
Telotristat ethyl blocks tryptophan hydroxylase, the enzyme that makes serotonin in your gut. Carcinoid tumors overproduce serotonin, causing severe diarrhea and flushing. By cutting serotonin production, the drug reduces diarrhea episodes by 40% in clinical trials [1].
In the TELESTAR and TELECAST phase 3 trials, patients taking 250 mg three times daily had 40% fewer diarrhea episodes compared to placebo within 4–8 weeks. The active metabolite, telotristat, is 29 times more potent at blocking tryptophan hydroxylase than the parent compound itself. This targeted enzyme inhibition makes telotristat ethyl unique among carcinoid syndrome treatments [1][4].
Your gut cells normally make serotonin to help with digestion and movement. Carcinoid tumors hijack this system and pump out 10–100 times more serotonin than normal. That flood of serotonin triggers your intestines to secrete water and speed up movement, causing watery diarrhea and cramping. Telotristat ethyl turns down the serotonin faucet at its source [1].
Most patients tolerate the 250 mg three-times-daily dose well, though nausea and headache occur in 10–15% of users. Weight maintenance is stable over 48 weeks of therapy, unlike some older carcinoid treatments. If you have liver disease or take certain medications, your doctor may adjust timing or monitor liver enzymes more closely [4][6].
Ask your doctor: 'How long until I notice fewer bathroom trips?' Most patients see improvement in 4–8 weeks. Keep a simple diarrhea diary (date, number of episodes) to show your clinician at follow-up visits.